Gliclazide:: Pharmacokinetic-pharmacodynamic relationships in rats

被引:13
作者
Stetinova, V.
Kvetina, J.
Pastera, J.
Polaskova, A.
Prazakova, M.
机构
[1] Acad Sci Czech Republic, Joint Res Ctr, Inst Expt Biopharmaceut, Hradec Kralove 50003, Czech Republic
[2] PROMED CA Praha AS, Hradec Kralove 50003, Czech Republic
[3] Acad Sci Czech Republic, Joint Res Ctr, Inst Expt Biopharmaceut, Hradec Kralove, Czech Republic
关键词
gliclazide; alloxan-induced diabetes mellitus; pharmacokinetics; rat;
D O I
10.1002/bdd.550
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The relationship between the pharmacokinetics of gliclazide and its antidiabetic efficacy were evaluated on the basis of experimental determination of changes with time in the plasma levels of this antidiabetic agent and those of glucose. The experiment included rats with both initial normal glycaemia and alloxan-induced hyperglycaemia (glycaemia increased by a minimum of 30%). Pharmacokinetic and pharmacodynamic parameters were examined in the interval of 30 to 180 min after p.o. administration of a single dose of 25 mg/kg of gliclazide. The drug was administered on day 4, following a single i.v. dose of either 50mg/kg of alloxan (hyperglycaemic group) or the injection vehicle (control group). Even though the biological availability of gliclazide was similar in both normoglycaemic and hyperglycaemic animals, the gliclazide-induced hypoglycaemizing response was not uniform: until 60 min, the decrease of glycaemia was smaller in animals with alloxan hyperglycaemia (23% decrease at 60 min) in contrast to the normoglycaemic animals (36% decrease at 60 min), at later times, the intensity of this hypoglycaemizing effect of gliclazide persisted in the hyperglycaemic animals, while in the normoglycaemic ones, a reversal of the hypoglycaemizing effect occurred. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:241 / 248
页数:8
相关论文
共 28 条
[1]   Anti-diabetic activity of Zingiber officinale in streptozotocin-induced type I diabetic rats [J].
Akhani, SP ;
Vishwakarma, SL ;
Goyal, RK .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2004, 56 (01) :101-105
[2]   Methodological issues in pharmacokinetic-pharmacodynamic modelling [J].
Bellissant, E ;
Sébille, V ;
Paintaud, G .
CLINICAL PHARMACOKINETICS, 1998, 35 (02) :151-166
[3]   SULFONYLUREA RECEPTORS, ION CHANNELS, AND FRUIT-FLIES [J].
BOYD, AE .
DIABETES, 1988, 37 (07) :847-850
[4]   Scavenging effect of melatonin on hydroxyl radicals generated by alloxan [J].
Brömme, HJ ;
Mörke, W ;
Peschke, E ;
Ebelt, H ;
Peschke, D .
JOURNAL OF PINEAL RESEARCH, 2000, 29 (04) :201-208
[5]   Metabolic control of β-cell function [J].
Deeney, JT ;
Prentki, M ;
Corkey, BE .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2000, 11 (04) :267-275
[6]   Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL [J].
Desfaits, AC ;
Serri, O ;
Renier, G .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (10) :1150-1156
[7]  
GAINES KL, 1988, J BIOL CHEM, V263, P2589
[8]   Cardiac sarcolemmal Na+-Ca2+ exchange and Na+-K+ ATPase activities and gene expression in alloxan-induced diabetes in rats [J].
Golfman, L ;
Dixon, IMC ;
Takeda, N ;
Lukas, A ;
Dakshinamurti, K ;
Dhalla, NS .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1998, 188 (1-2) :91-101
[9]   METABOLISM OF ARACHIDONIC-ACID IN NEUTROPHILS FROM ALLOXAN-DIABETIC RABBITS [J].
GRECO, NJ ;
MILKS, MM ;
PANGANAMALA, RV .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1991, 42 (04) :201-208
[10]   ALLOXAN-INDUCED DIABETES - EVIDENCE FOR HYDROXYL RADICAL AS A CYTOTOXIC INTERMEDIATE [J].
HEIKKILA, RE ;
WINSTON, B ;
COHEN, G ;
BARDEN, H .
BIOCHEMICAL PHARMACOLOGY, 1976, 25 (09) :1085-1092